Home » Topics » Regulatory » EMA

EMA
RSS

Biogen gives update on regulatory applications for nusinersen in E.U., U.S.

Oct. 31, 2016

EMA accepts for review MAA for niraparib in ovarian cancer

Oct. 28, 2016

EMA issues positive opinion recommending orphan drug designation for La Jolla's LJPC-401

Oct. 25, 2016

EMA awards priority medicine designation to CymaBay Therapeutics' MBX-8025

Oct. 21, 2016

EMA gives orphan drug designation to gene therapy program ABO-102

Oct. 19, 2016

EMA grants orphan designation to Iomab-B

Oct. 19, 2016

EMA grants PRIME access to Atara's EBV-CTL

Oct. 19, 2016

PTC Therapeutics offers U.S. and E.U. regulatory update on Translarna

Oct. 18, 2016

Positive opinion handed down in E.U. for SomaKit TOC

Oct. 18, 2016

EMA gives orphan drug designation to Eiger's exendin 9-39

Oct. 18, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...